Viamet Pharmaceuticals Initiates Phase 1/2 Clinical Trial of Novel Prostate Cancer Therapy, VT-464

Viamet Pharmaceuticals has begun a Phase 1/2 clinical trial of its drug for the treatment of castration-refractory prostate cancer.... [more]

View complete Press Release article